13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
35 檔
38.1%
In Q1 2025, Nan Fung Group Holdings Ltd's U.S. equity holdings reached a combined market value of $131.5M, distributed across 35 disclosed stock positions.
In Q1 2025, Nan Fung Group Holdings Ltd displayed an active expansion posture, initiating 29 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HRMY | Harmony Biosciences Holdings | Stock-Other | 9.98% | +0.13% | — | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 7.99% | -4.52% | +17.95% | |
| 3 | ILMN | Illumina Inc | Stock-Healthcare | 7.71% | — | — | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.66% | — | +11.24% | |
| 5 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 7.48% | — | +7.95% | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.39% | — | +17.10% | |
| 7 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.79% | — | — | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 4.64% | — | — | |
| 9 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.34% | — | +48.67% | |
| 10 | ✓ | Merus N V | Stock-Other | 4.12% | — | — | |
| 11 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.49% | -0.44% | -21.38% | |
| 12 | REPL | Replimune Group Inc | Stock-Other | 3.29% | — | +28.75% | |
| 13 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.21% | -0.13% | +6.74% | |
| 14 | INCY | Incyte CORP | Stock-Healthcare | 2.91% | +0.46% | -11.94% | |
| 15 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 2.87% | +0.15% | — | |
| 16 | TRML | Tourmaline Bio Inc | Stock-Other | 2.82% | — | +21.38% | |
| 17 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.12% | +0.63% | — | |
| 18 | EXEL | Exelixis Inc | Stock-Healthcare | 1.93% | — | — | |
| 19 | GERN | Geron CORP | Stock-Other | 1.78% | — | — | |
| 20 | ASND | Ascendis Pharma A/S | Stock-Other | 1.73% | -2.57% | EXIT | |
| 21 | LAB | Standard Biotools Inc | Stock-Other | 1.66% | — | — | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.45% | — | — | |
| 23 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.40% | +0.09% | — | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.35% | +0.29% | +551.16% | |
| 25 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.69% | +0.57% | — | |
| 26 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.56% | +1.20% | — | |
| 27 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.51% | -0.01% | — | |
| 28 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.48% | — | — | |
| 29 | CLYM | Climb Bio Inc | Stock-Other | 0.46% | — | — | |
| 30 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.38% | — | — | |
| 31 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.36% | -0.24% | — | |
| 32 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.21% | — | — | |
| 33 | ✓ | Bolt Projs Hldgs Inc | Stock-Other | 0.20% | — | — | |
| 34 | ✓ | Affimed N V | Stock-Other | 0.02% | — | — | |
| 35 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | HRMY | Harmony Biosciences Holdings | +3.2% | — | Trim |
| 2 | XENE | Xenon Pharmaceuticals Inc | +3.2% | +48.67% | Trim |
| 3 | EXEL | Exelixis Inc | +1.6% | — | Unchanged |
| 4 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.9% | — | Add |
| 5 | ALXO | Alx Oncology Holdings Inc | -0.6% | — | Add |
| 6 | BOLT1EUR | Bolt Biotherapeutics Inc | -5.2% | — | Unchanged |
| 7 | ✓ | Eargo Inc | — | EXIT | Sold out |
| 8 | ULCC | Frontier Group Holdings, Inc. | — | EXIT | Sold out |
| 9 | ✓ | — | EXIT | Sold out | |
| 10 | OCS | Oculis Holding AG | — | NEW | New buy |
| 11 | ILMN | Illumina Inc | — | NEW | New buy |
| 12 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 13 | ZLAB | Zai Lab Ltd-adr | — | NEW | New buy |
| 14 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 15 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 16 | GRTX | Galera Therapeutics Inc | — | EXIT | Sold out |
| 17 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 18 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 19 | ✓ | Merus N V | — | NEW | New buy |
| 20 | NVTA1EUR | Invitae CORP | — | EXIT | Sold out |
| 21 | ONC | Beone Medicines Ltd-adr | — | NEW | New buy |
| 22 | REPL | Replimune Group Inc | — | NEW | New buy |
| 23 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 24 | ✓ | New Frontier Health CORP | — | EXIT | Sold out |
| 25 | INCY | Incyte CORP | — | NEW | New buy |
| 26 | RXRX | Recursion Pharmaceuticals-a | — | NEW | New buy |
| 27 | TRML | Tourmaline Bio Inc | — | NEW | New buy |
| 28 | VIR | Vir Biotechnology Inc | — | EXIT | Sold out |
| 29 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 30 | ✓ | Sierra Oncology Inc Com | — | EXIT | Sold out |
| 31 | ARDX | Ardelyx Inc | — | EXIT | Sold out |
| 32 | GERN | Geron CORP | — | NEW | New buy |
| 33 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 34 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 35 | LAB | Standard Biotools Inc | — | NEW | New buy |
| 36 | OTICEUR | Otonomy Inc | — | EXIT | Sold out |
| 37 | ACAD | Acadia Pharmaceuticals Inc | — | NEW | New buy |
| 38 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 39 | ✓ | — | EXIT | Sold out | |
| 40 | RUBYUSD | Rubius Therapeutics Inc | — | EXIT | Sold out |
| 41 | RETAEUR | Reata Pharmaceuticals Inc-a | — | EXIT | Sold out |
| 42 | KYMR | Kymera Therapeutics Inc | — | NEW | New buy |
| 43 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 44 | RANI | Rani Therapeutics Holdings-a | — | NEW | New buy |
| 45 | BCYC | Bicycle Therapeutics Plc-adr | — | NEW | New buy |
| 46 | IDIEUR | Fluent Inc | — | EXIT | Sold out |
| 47 | CLYM | Climb Bio Inc | — | NEW | New buy |
| 48 | TRDA | Entrada Therapeutics Inc | — | NEW | New buy |
| 49 | ✓ | Synlogic Inc | — | EXIT | Sold out |
| 50 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 35 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HRMY, OCS, ILMN) accounted for 38.1% of total reported equity market value during Q1 2025.
Top New Position Initiated
OCS
市值: $9.8M
Top Position Liquidated / Trimmed
EARGO INC
前期市值: $115.2M
During Q1 2025, Nan Fung Group Holdings Ltd's top holdings by market value included HRMY (10.0%)、OCS (8.0%)、ILMN (7.7%). The largest single position, HRMY, represented 10.0% of total portfolio value.
In Q1 2025, Nan Fung Group Holdings Ltd made 51 total portfolio adjustments, initiating 29 new buys, adding to 2 positions, trimming 2 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.